Vestis Corp and Nuvation Bio Post Strong Q2 Results With EBITDA Surges and Raised Guidance

The Quick Take

• Vestis Corp EBITDA surged 23% and the company raised free cash flow guidance after transformation progress
• Nuvation Bio's IBTROZI captured ROS1-positive lung cancer leadership with $31.7M Q2 revenue
• Both companies demonstrate strong execution momentum across services and oncology verticals

Synthesized from 2 sources.

Vestis Corporation's Q2 2026 results reflect the success of a multi-year transformation strategy aimed at operational standardization across its distributed uniform and workplace services business. A 23% surge in adjusted EBITDA, coupled with raised free cash flow guidance, signals that Vestis has moved beyond integration disruption following its 2023 spin-off from Aramark and is now generating self-sustaining cash flows. The company's focus on closing performance gaps across underperforming regional market centers has resulted in measurable improvement in client retention metrics — a leading indicator for long-cycle service contracts typically running three to five years.

Nuvation Bio's IBTROZI launch trajectory in ROS1-positive non-small cell lung cancer is a textbook biotech commercial ramp. Revenue of $31.7 million in Q2 — with 25% sequential growth — demonstrates strong physician and payer acceptance in a niche oncology indication with high unmet need. A cash position of $661 million provides Nuvation with substantial runway to pursue label expansion into ROS1-positive gastric and colorectal indications, which represent meaningful revenue upside if clinical data supports regulatory filings. The company's lean operating structure keeps burn rate manageable relative to its reserves.

Vestis investors should monitor market center performance and whether the free cash flow raise is driven by working capital improvements or sustainable EBITDA growth — a critical valuation distinction. Key competitor dynamics include Cintas and Unifirst, which have both signaled aggressive pricing in the uniform services market. For Nuvation Bio, the highest-value near-term catalyst is any Phase 2 data readout in expanded indications. Investors should track ROS1 inhibitor market dynamics, particularly any new competitor approvals that could erode IBTROZI's first-mover advantage.